HYL — Hyloris Pharmaceuticals SA Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapNeutral

Annual cashflow statement for Hyloris Pharmaceuticals SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	ARS	ARS	PRESS	PRESS
Standards:	IFRS	IFRS	IFRS	—	—
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-5.27	-7.14	-11.6	-11.8	-15.8
Depreciation
Non-Cash Items	-0.003	1.89	0.769	0.458	0.897
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-2.59	0.101	-0.577	-1.38	1.79
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-4.56	-4.57	-11.3	-12.5	-12.7
Capital Expenditures	-1.23	-0.623	-1.06	-0.739	-0.723
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	0.002	-0.01	-2.01	-11.2	10.4
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-1.23	-0.633	-3.08	-11.9	9.65
Financing Cash Flow Items	-0.004	74.2	—	12.5	0
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	3.31	69.4	-0.062	7.84	-0.188
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-2.48	64.2	-14.4	-16.6	-3.26